New IBD medications, including biosimilars, have been approved since the creation of this resource. A revised version of the program will be developed once this version expires. View a listing of recently approved IBD medications: http://www.ccfa.org/assets/pdfs/recently-approved-treatments.pdf
- Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014 Sep 5. [Epub ahead of print]. doi: 10.1016/j.mayocp.2014.07.002.
- Jones J, Peña-Sánchez JN. Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach. Gastroenterol Clin North Am. 2014;43(3):425-440.
- Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment for inflammatory bowel disease, from clinical trials and practice. Gastroenterology. 2014 Aug 12. [Epub ahead of print]. doi: 10.1053/j.gastro.2014.08.003.
- Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109(7):994-1004.
Hans Herfarth, MD, PhD, has affiliations with Celltrion, Janssen, Pfizer (Consultant).
Miguel Regueiro, MD, has affiliations with AbbVie, Janssen, Takeda, UCB (Consultant).
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and Crohn's & Colitis Foundation of America. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.
Other health care professionals are awarded .10 continuing education units (CEUs), which are equal to 1.0 contact hours. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.
Estimated time to complete: 60 minutes
There is no fee for this educational activity.
This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation of America. This activity is supported by independent educational grants from Actavis, Prometheus, Takeda and UCB.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credits™.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 65% or higher on the post-test to receive credit for this activity. You will have three attempts to take the post-test.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above
For video playback, install the latest version of Flash or Quicktime.
|Supported Phones & Tablets: |
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above